Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Post-Transplant Events

Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT

Abstract

Human CMV (HCMV)-directed preemptive therapy has helped to improve the outcome following allo-SCT. In this study, we evaluated the safety and efficacy of a late mRNA-based (NucliSens CMV pp67) anti-HCMV treatment strategy. A prospective randomized multicenter pilot trial was performed comparing PCR-based, with late mRNA-based preemptive HCMV-directed antiviral therapy in patients after allo-SCT. In all, 133 patients were randomized in three different centers at the time of transplant, 130 of whom are evaluable. Viral screening was performed weekly. Antiviral therapy was initiated at the second consecutive positive PCR result, or at the first detection of late mRNA. The therapy was stopped if clearance of HCMV DNA or late mRNA was demonstrated after 14 days of antiviral therapy. If HCMV infection persisted, antiviral therapy was continued in a reduced dose. The median duration of antiviral therapy during the first treatment episode was 28 days for PCR-, and 19 days for mRNA-screened patients (P<0.02). However, the overall duration of antiviral therapy, as well as the incidence of HCMV disease and the OS at day 100 after transplantation was comparable between the two study groups. We conclude that late mRNA-based anti-HCMV therapy may show comparable safety and efficacy with PCR-based therapy in patients after allo-SCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–1607.

    Article  CAS  PubMed  Google Scholar 

  2. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA . A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005–1011.

    Article  CAS  PubMed  Google Scholar 

  3. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.

    CAS  PubMed  Google Scholar 

  4. Ehrnst A, Barkholt L, Lewensohn-Fuchs I, Ljungman P, Teodosiu O, Staland A et al. CMV PCR monitoring in leucocytes of transplant patients. Clin Diagn Virol 1995; 3: 139–153.

    Article  CAS  PubMed  Google Scholar 

  5. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  6. Zaia JA . Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999–1004.

    Article  PubMed  Google Scholar 

  7. Boeckh M, Huang M, Ferrenberg J et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42: 1142–1148.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA . Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108–113.

    Article  CAS  PubMed  Google Scholar 

  9. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J . Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543–558.

    Article  PubMed  Google Scholar 

  10. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757–763.

    Article  CAS  PubMed  Google Scholar 

  11. Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H et al. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 53–60.

    Article  CAS  PubMed  Google Scholar 

  12. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD . Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032–2036.

    Article  CAS  PubMed  Google Scholar 

  13. Boriskin YS, Fuller K, Powles RL, Vipond IB, Rice PS, Booth JC et al. Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation. J Clin Virol 2002; 24: 13–23.

    Article  CAS  PubMed  Google Scholar 

  14. Gerna G, Baldanti F, Middeldorp JM, Furione M, Zavattoni M, Lilleri D et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1999; 37: 902–911.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G et al. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 181–187.

    Article  CAS  PubMed  Google Scholar 

  16. Grundy JE, Ehrnst A, Einsele H, Emery VC, Hebart H, Prentice HG et al. A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood. J Clin Microbiol 1996; 34: 1166–1170.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Blok MJ, Goossens VJ, Vanherle SJ, Top B, Tacken N, Middeldorp JM et al. Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification. J Clin Microbiol 1998; 36: 1341–1346.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J . Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adriaanse H et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991; 35: 273–286.

    Article  CAS  PubMed  Google Scholar 

  20. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA . Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104–1110.

    CAS  PubMed  Google Scholar 

  21. Hebart H, Muller C, Loffler J, Jahn G, Einsele H . Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861–868.

    CAS  PubMed  Google Scholar 

  22. Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF . Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma. J Clin Microbiol 1998; 36: 2220–2222.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854–860.

    Article  CAS  PubMed  Google Scholar 

  24. Ljungman P . Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186 (Suppl 1): S99–S109.

    Article  PubMed  Google Scholar 

  25. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  26. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–178.

    Article  CAS  PubMed  Google Scholar 

  27. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L . Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781–1782.

    CAS  PubMed  Google Scholar 

  28. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101: 5053–5060.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Swedish Cancer Fund. The study was supported by bioMérieux bv, Boxtel, The Netherlands.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Einsele.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hebart, H., Lengerke, C., Ljungman, P. et al. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT. Bone Marrow Transplant 46, 408–415 (2011). https://doi.org/10.1038/bmt.2010.136

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.136

Keywords

Search

Quick links